Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
78798.730.3687%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Context Therapeutics Inc

CNTXNASDAQ
Trade with Public
Trade with Public
$0.3617
-0.0013-0.36%
At close: Sep 4, 5:00 PM EST
$0.3512
-0.0105-2.9%
After Hours: Sep 4, 6:48 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Context Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Context Therapeutics (CNTX).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

1S.Buy
8Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$6Upside to Avg. PT+1520.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 16, 2026Maxim GroupJason McCarthyPT CutBuy$8→$4
Mar 24, 2026D. Boral CapitalJason KolbertMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
Benzinga Newsdesk

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved